Jefferson University Hospitals

Provider Profile

Matthew Carabasi, MD

Jefferson University Physician

Academic Title: Professor

Hematology - Medical Oncology
Medical Oncology
Medical Oncology - Bone Marrow Transplant
Medical Oncology - Hematologic Malignancies
Medical Oncology - Leukemia/Lymphoma

Make An Appointment

Click to call 1-800-JEFF-NOW (800-533-3669) or

Office Locations

925 Chestnut Street
Suite 420A
Philadelphia PA 19107
Phone: (215) 955-8874
Fax: (215) 955-2340

Medical Services

Board Certifications

  • Internal Medicine
  • Medical Oncology

Hospital Affiliation / Admitting Privileges

  • Thomas Jefferson University Hospital
  • Methodist Hospital Division of Thomas Jefferson University Hospital

Awards and Honors

Philadelphia Magazine's Top Docs 2016,2015,2014,2013,2012,2011,2010


Dr. Carabasi also specializes in stem cell transplantation.


  • Jefferson Medical College, Medical School


  • Hahnemann University Hospital


  • Hahnemann University Hospital


  • Memorial Sloan-Kettering Cancer Center

Jefferson physicians accept most health insurance plans, including those listed below. However, plan acceptance may vary by practice and may be subject to change. If you have questions about whether a specific physician accepts your insurance, please contact your insurance company.

Insurances Accepted

  • Aetna
  • Aetna PA Employee Benefit Trust Fund (PEBTF)
  • Amer Assoc Retired Persons (AARP)
  • AmeriHealth
  • Amerihealth Caritas
  • AmeriHealth Comprehensive
  • AmeriHealth HMO
  • AmeriHealth Major Medical
  • AmeriHealth Personal Choice
  • BC BS Special Care
  • Blue Choice
  • Blue Cross/Blue Shield
  • Blue Cross/Blue Shield of Delaware
  • Cigna Healthspring
  • Cigna PPO, POS
  • Consumer Health Network PPO
  • CorVel
  • Coventry/Health America
  • Delaware Blue Cross/Blue Shield
  • Devon
  • Empire BC/BS
  • Employers Health Network PPO
  • Evolutions (Guardian Resources)
  • Federal BCBS
  • First Health Network
  • Galaxy
  • Geisinger Health Plan
  • Health America PPO
  • Health Management Network PPO
  • Horizon Blue Cross/Blue Shield
  • Horizon HMO
  • HumanaChoicePPO,Medicare,GoldPlusHMO
  • Inter-County Health Plan
  • Intergroup Preferred
  • Jeff Plus
  • Keystone 65 HMO
  • Keystone First VIP Choice
  • Keystone First/Connect
  • Keystone Health Plan East
  • Medallion of New Jersey
  • Medicaid of PA
  • Medicare
  • Mercy LIFE
  • MultiPlan Inc.
  • NJ Blue Shield
  • NJ Plus
  • Oxford of PA
  • Personal Choice (GPPPN)
  • Personal Choice 65
  • PlanCare America
  • Postal Workers/Mailhandlers
  • PPO Next
  • Preferred Care PPO
  • Premier Blue
  • Prime Health Services, Inc.
  • Private Healthcare Systems (PHCS)
  • Qualcare
  • Tricare
  • United Healthcare
  • UPMC HMO,PPO ReadingHspEmpONLY
  • UPMC Medicare HMO
  • US Family Health Plan

Recent Publications

Higher rates of relapse in maternal recipients of haploidentical hematopoietic stem cell transplantation from adult offspring donors for AML and myelodysplastic syndrome

Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States

Improved survival after acute graft-versus-host disease diagnosis in the modern era

Acquired uniparental disomy in chromosome 6p as a feature of relapse after T-cell replete haploidentical hematopoietic stem cell transplantation using cyclophosphamide tolerization

A Two-Step Haploidentical Versus a Two-Step Matched Related Allogeneic Myeloablative Peripheral Blood Stem Cell Transplantation

A two-step approach to myeloablative haploidentical transplantation: Low nonrelapse mortality and high survival confirmed in patients with earlier stage disease

Clostridium difficile colonization and disease in patients undergoing hematopoietic stem cell transplantation

No increased mortality from donor or recipient hepatitis B- and/or hepatitis C-positive serostatus after related-donor allogeneic hematopoietic cell transplantation

Allogeneic Hematopoietic Cell Transplantation for Advanced Polycythemia Vera and Essential Thrombocythemia

A2-step approach to myeloablative haploidentical stem cell transplantation: A phase 1/2 trial performed with optimized T-cell dosing

Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: How much progress has been made?

Adenovirus DNA polymerase is recognized by human CD8+T cells

Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia

A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+hematologic malignancies

Marrow ablative chemotherapy with hematopoietic stem cell rescue

Improved Outcomes in Intermediate- and High-Risk Aggressive Non-Hodgkin Lymphoma after Autologous Hematopoietic Stem Cell Transplantation Substituting Intravenous for Oral Busulfan in a Busulfan, Cyclophosphamide, and Etoposide Preparative Regimen

Comparison of graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations

Severity of chronic graft-versus-host disease: Association with treatment-related mortality and relapse

Fatal sickle cell crisis after granulocyte colony-stimulating factor administration [1]

NCCN Practice Guidelines for Acute Myelogenous Leukemia.